§ BIOTECHNOLOGY
USD · Biotechnology

CADL

CANDEL THERAPEUTICS INC
USDSector · Biotechnology
LAST
n/a
n/aPREV CLOSE · n/a
§ 01 · PRICE
Price action
1D5D1M6MYTD1YMAX

§ 03 · SIGNAL STACK · WHAT THE INPUTS SAY

§ 05 · WHO OWNS IT
Top institutional holders
All holders →
FundShares% portΔ Q/Q
Fidelity Management8.6M0.0%+33%
RTW INVESTMENTS, LP6.4M0.3%n/a
ACORN CAPITAL ADVISORS, LLC3.5M4.9%+36%
Saturn V Capital Management LP2.9M2.6%n/a
Portolan Capital Management, LLC2.9M0.8%+71%
VANGUARD CAPITAL MANAGEMENT LLC2.5M0.0%n/a
AC INTELLIGENCE

Top institutional owners for CADL as of the most recent 13F reporting period (Q1 2026 · Period ended Mar 31). Δ Q/Q reflects share-count change vs. the prior filing — positive green means adding, negative red means trimming. Cross-reference with the ownership-mix bars below to see which strategy cohort is driving the flow.

§ 06 · WHO OWNS IT · BY STRATEGY

OTHER36.1% · 0 holders
OTHER37.9% · 76 holders
QUALITY / COMPOUNDER15.7% · 5 holders
PASSIVE / INDEX5.9% · 7 holders
DEALER / BANK2.6% · 16 holders
TACTICAL / MACRO1.8% · 4 holders
SYSTEMATIC / QUANT0.1% · 3 holders
INCOME / DEFENSIVE0.0% · 4 holders
AC INTELLIGENCE

Ownership mix by behavioral cohort. Top bars indicate which style of capital dominates the float — passive indexing, quality compounders, dealer/bank, systematic quant, etc. Big quality-compounder share means concentrated active conviction; heavy passive share means flows are dictated by index rebalances, not fundamentals.

§ 07 · INSIDER ACTIVITY · LAST 180 DAYS

NO INSIDER FILINGS
AC INTELLIGENCE

No Form 4 filings on record for CADL in the last 180 days.

§ 08 · COVERAGE · OUR RECENT NOTES

No notes mention CADL yet.